Tumor located peripherally within the lung; NOTE: peripheral is defined as not touching any surface within  cm of the proximal bronchial tree in all directions; patients with non-peripheral (central) tumors are NOT eligible
Extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > . cm, in sum of maximal diameters (e.g. presence of one . cm metastatic lymph node or two  cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > . cm
>  cm in any dimension
Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):            \r\n* Positive capillary-lymphovascular space involvement and one of the following:                \r\n** Deep third penetration\r\n** Middle third penetration, clinical tumor >=  cm\r\n** Superficial third penetration, clinical tumor >=  cm\r\n* Negative capillary-lymphatic space involvement                \r\n** Middle or deep third penetration, clinical tumor >=  cm
Greatest tumor dimension of all sites must be =< . cm or <  cm^
Presence of greater than  cm x  cm residual tumor enhancement on postoperative MRI;
Radiographic evidence of measurable disease tumor lesion (? cm in greatest dimension) or nodal disease (>.cm in greatest dimension)
Tumor size ?. cm in greatest diameter in the axis parallel to the treatment probe AND ?. cm in the axis anti-parallel to the treatment probe AND ?. cm in Anterior/ Posterior dimension. Tumor size ?. cm in greatest diameter as measured by breast ultrasound, mammogram and/or MRI. The largest dimension measured will be used to determine eligibility.
Six or more caf-au-lait spots (>= . cm in prepubertal subjects or >= . cm in postpubertal subjects)
Stage at presentation: cT-cT, cN-cN, cM
Participants with tumor =<  cm proximity to the ventricles will be allowed to enroll; however the study agent (rQNestin.v.) may not be injected in any area that is within  cm of the ventricle regardless of where the tumor is located
Tumors extend  cm or more into the stomach
Palpable splenomegaly ? cm below the lower costal margin in the midclavicular line as assessed by physical examination
Relapsed or refractory, histologically confirmed follicular lymphoma, grade I, II, or IIIa which requires therapy defined by at least one of the following:\r\n* Constitutional symptoms \r\n* Cytopenias\r\n* High tumor burden (single mass >  cm, three masses >  cm, symptomatic splenomegaly, organ compression or compromise, ascites, pleural effusion)
Radiographically measurable disease with a demarcated nodal lesion at least . cm in its largest dimension or a target extranodal lesion at least . cm in its largest dimension
Unifocal liver tumors not to exceed . cm in greatest axial dimension; multifocal lesions will be restricted to lesions that can be treated within a single target volume within the same liver segment and to an aggregate of  cm as long as the dose constraints to normal tissue can be met
BE length ?cm excluding visible BE islands, and Prague Classification C ? / M ?
Large (>cm) hiatal hernia
For diseases other than Waldenstrom's macroglobulinemia (WM), presence of radiographically measurable presence of ?  lesion that measures ? . cm in the longest dimension (LD) and ? . cm in the longest perpendicular dimension (LPD)
Bulky metastases, defined as any tumor nodule or lymph nodes >  cm in greatest dimension on axial images on pre-treatment CT, PET/CT, or magnetic resonance imaging (MRI)\r\n* Note: patients with bulky (>  cm) disease for whom gross total cytoreduction is deemed feasible by a surgeon (with confirmation by a second surgeon after radiologic review) are eligible for participation in the context of cytoreductive surgery
Measurable disease by tumor imaging with at least one lesion >= . cm in at least one dimension
Low tumor burden as defined by Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria ():\r\n* No tumor mass (nodal or extranodal) >=  cm in one dimension on computed tomography (CT)\r\n* Fewer than  ( or less) nodal masses >  cm\r\n* No systemic or B symptoms\r\n* No splenomegaly greater than  cm by CT scan\r\n* No risk of organ compression  ureteral, orbital, neurological, gastrointestinal\r\n* No leukemic phase (> . x ^/L circulating FL cells in the blood as detected by complete blood count [CBC] with differential and smear)\r\n* No cytopenias  absolute neutrophil count (ANC) <  or platelets < ,
Measurable disease of at least . cm as documented by radiographic technique
Up to  lesions may be included; for a single lesion the sum of three orthogonal diameters can be no more than  cm; for multiple lesions, no lesion can have a sum of orthogonal diameters greater than  cm
Has a target lesion/s for SBRT that demonstrate any of the following:\r\n* located within  cm of the proximal bronchial tree\r\n* >  cm (>  cc) in greatest dimension
Largest tumor =<  cm.
Subjects must have at least one extra-central nervous system (CNS), non-bone tumor lesion amenable for IT injection ? . cm and that is not in close proximity or encasing crucial structures such as major blood vessels, trachea, nerve bundles etc.
Lesion to be resected is more than  cm
Total volume of metastatic disease more than  cm^ excluding lesion to be resected
Lesions with a height >  cm measured from the skin surface are not eligible for this protocol.
Two lesions can be in close proximity (i.e. within  cm of each other) if they meet radiation SBRT normal tissue toxicity requirements
Biopsy-amenable residual disease in the breast measuring >=  cm in at least one dimension on ultrasound cm in at least one dimension on ultrasound
The tumor must be at least  cm in maximum dimension
Three or fewer total sites of active disease (at least one site of active disease to be treated on study must be confined to the abdomen or pelvis excluding liver and must be <  cm in greatest dimension as determined by pre-screening cross-sectional imaging)
Locally advanced/borderline resectable HCC as defined by:\r\n* Solitary tumor >  cm OR\r\n* Unilobar multifocal disease either with >  tumors or one tumor >  cm OR\r\n* Bilobar disease with adequate future liver remnant, still technically resectable OR\r\n* High risk disease features (alpha-fetoprotein [AFP] > , or tumor >  cm with macrovascular invasion)\r\n* No extrahepatic spread, no nodal disease, and no bilateral left and right branch portal vein involvement
Patients with PTCL should have radiographically measurable disease >= . cm.
Patient must have < . cm midline shift pre-operatively
Clinical =< . cm unifocal lesion
Presence of one or more cutaneous lesions (measuring at least  cm x  cm in size; if only one lesion is present it should be up to the investigator discretion to determine eligibility)
Total volume of lesions =<  cm^
Subject is surgical candidate for TURBT as part of normal NMIBC treatment plan. For part , successful completion of TURBT procedure. For part , successful completion of TURBT procedure with one marker lesion left intact; the marker lesion should be > . cm and < . cm in diameter.
Patients tumor(s) to be treated is(are) =< . cm or =<  cm^
Patient must have at least  measurable lesions that are >= . cm in one dimension; one of the lesions must be >= . cm and is amenable to image-guided cryoablation and multiple vaccine injections as determined by interventional radiology and principal investigator (PI) (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures)
In the context of this clinical trial, a lesion suitable for LITT is single, enhancing, supratentorial, at least  cm from inner table of skull over the hemispheric convexity, and >  cm, but <  cm in cross-sectional dimension, including thalamic tumor (=<  cm).
Palpable spleen of >  cm below the left subcostal margin on physical examination at the screening visit OR
Lymphadenopathy in the retroperitoneum: at least one lymph node - cm in greatest dimension, no lymph node >  cm in greatest dimension, no more than  lymph nodes - cm in greatest dimension\r\n* Axial imaging of lymphadenopathy within  weeks of the date of RPLND\r\n* Retroperitoneal lymphadenopathy must be within the RPLND template
T with T ?.cm, T or T by at least one radiographic or clinical measurement
Any T, Tis, T < . cm, T; or N-; or M BC.
Any one hepatocellular carcinoma >  cm
Extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > . cm, in sum of maximal diameters (e.g. presence of one . cm metastatic lymph node or two  cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > . cm
Clinically =<  cm unifocal lesion by imaging or physical examination
Maximum projected treatment length  cm and width  cm, which are the dimensions of the largest available CivaSheet
Must have stage ,  or  disease, with either high tumor burden by GELF criteria and/or FLIPI - (for FL)\r\n* To meet GELF criteria, patient must have at least one criterion:\r\n** Nodal or extranodal mass >  cm (document here the largest/longest single nodal or extranodal mass diameter)\r\n** At least  nodal masses: each > . cm in longest dimension\r\n** Systemic symptoms due to lymphoma or B symptoms\r\n** Splenomegaly with spleen >  cm by computed tomography (CT) scan\r\n** Evidence of compression syndrome (e.g., ureteral, orbital, gastrointestinal) or pleural or peritoneal serous effusion due to lymphoma (irrespective of cell content)\r\n** Leukemic presentation (> . x ^/L malignant circulating follicular cells)\r\n** Cytopenias (absolute neutrophil count < . X ^/L, hemoglobin <  gm/dL, and/or platelets <  x ^/L) AND/OR\r\n* To meet FLIPI criteria for FL, patient must have a score of , , or  (one point each for below criterion):\r\n** Age >  years\r\n** Ann Arbor stage III-IV\r\n** Hemoglobin level <  mg/dL\r\n** >=  nodal areas\r\n** Serum lactate dehydrogenase (LDH) level above normal\r\n* FLIPI; each patient should be assessed for the presence or absence of the following  adverse prognostic factors:\r\n** Age (>  years versus [vs.]  years or less)\r\n** Hemoglobin level (<  g/L vs.  g/L or higher)\r\n** Beta-microglobulin (above normal vs. normal or below)\r\n** Largest involved lymph node (>  cm vs. cm or lower)\r\n** Bone marrow (involved by histology vs. not involved)
Lesion size >=  cm in maximum dimension or >=  cm and deemed a poor candidate for other ablative approaches
Pancreatic or periampullary tumors must be less than . cm in greatest axial dimension at the time of treatment planning
Measurable disease, defined as >= . cm on imaging assessment
Patient may have more than one site of recurrent or metastatic disease but only one lesion that is >=  cm in size will be injected (if in the lung, the lesion must be >=  cm and adjacent to the pleura in the lung)
Tumor =<  cm from anal verge as determined by MRI or endoscopy
An index lesion measuring between cm  cm that is amenable to hypofractionated radiation therapy at the discretion of the treating radiation oncologist\r\n* Index lesions in the pancreas are excluded in the second cohort
The target lesion must measure at least  mm in at least one dimension, and no more than  cm in any dimension
Patients with residual tumor after surgery (any single site) exceeding  cm in maximum dimension.
MRI demonstration of an enhancing mass of more than  cm^ and less than  cm^
Subjects who have had radiotherapy to a target within  cm of the IVC tumor thrombus
Patients must have probable (i.e., clinically suspicious) or histologically/cytologically confirmed, primary or recurrent, malignant neoplasm, malignant neuroendocrine tumor, or carcinoma in situ (any stage)\r\n* Malignant neoplasm, malignant neuroendocrine tumor, or carcinoma in situ will be defined as\r\n** Malignant neoplasm of lip, oral cavity, or pharynx (International Classification of Disease--Clinical Modification [ICD--CM] codes - [or corresponding ICD--CM codes]) \r\n** Malignant neoplasm of digestive organs or peritoneum (ICD--CM codes - [or corresponding ICD--CM codes])\r\n** Malignant neoplasm of respiratory or intrathoracic organs (ICD--CM codes - [or corresponding ICD--CM codes]) \r\n** Malignant neoplasm of bone, connective tissue, skin, or breast (ICD--CM codes - [or corresponding ICD--CM codes])\r\n** Malignant neoplasm of genitourinary organs (ICD--CM codes - [or corresponding ICD--CM codes])\r\n** Malignant neoplasm of other or unspecified sites (ICD--CM codes - [or corresponding ICD--CM codes])\r\n** Malignant neuroendocrine tumor (ICD--CM codes .--, . [or corresponding ICD--CM codes])\r\n** Carcinoma in situ (ICD--CM codes - [or corresponding ICD--CM codes])
Clinical or tissue diagnosis of benign neuroendocrine tumor, benign neoplasm, neoplasm of uncertain behavior, or neoplasm of unspecified nature \r\n* Benign neuroendocrine tumor (ICD--CM codes .-. [or corresponding ICD--CM codes]) \r\n* Benign neoplasms (ICD--CM codes - [or corresponding ICD--CM codes]) \r\n* Neoplasm of uncertain behavior (ICD--CM codes - [or corresponding ICD--CM codes]) \r\n* Neoplasm of unspecified nature (ICD--CM codes  [or corresponding ICD--CM codes])
Patients with MCL must be symptomatic and need immediate therapy; symptoms and nature of MCL include any of the following: \r\n* Blastoid variant\r\n* Pleomorphic variant\r\n* B symptoms\r\n* Mantle Cell International Prognostic Score (MIPI) > \r\n* Ki- >= %\r\n* Bulky tumors >  cm or in case of >=  tumors, each >=  cm in diameter\r\n* Disease threatening organ function\r\n* Elevated lactate dehydrogenase (LDH)\r\n* Peripheral blood white blood cell (PB WBC) > ,\r\n* Pancytopenia due to bone marrow MCL\r\n* Patients choice due to anxiety\r\n* Pain due to lymphoma\r\n* Somatic mutations in the TP, c-MYC or NOTCH genes\r\n* Size of spleen >=  cm
Preoperative proctoscopy confirming tumor extent as no less than  cm and no greater than  cm from the anal verge
Presence of an index lesion >=  cm amenable to hypofractionated radiotherapy
Subjects with tumors lying <  cm from sensitive structures
Patients with primary tumors exceeding  cm in length or  cm in width
Patients with sub-optimal resection (any single tumor larger than  cm)
Patients must be no taller than . m ( feet  inches), and no wider from elbow to elbow in the supine position than  cm
Patients will have no more than  distinct lesions within the brain; at least  lesion must be a minimum of  cm in greatest dimension, no larger than  cm which will be treatable by fractionated stereotactic radiosurgery
Single tumor less than  cm
Up to  tumors all less than  cm
The tumor lesion is - cm from anal verge
T (>  cm), T, T, node positive (other than Nmi), or M disease
Subjects must have >= . cm of inflammatory breast cancer (IBC) on core ( cores)\r\n* NOTE: If the core is less than . cm, the subjects may be considered for inclusion based on the pathologists review of biopsy slides
Pancreatic or periampullary tumors must be less than . cm in greatest axial dimension at the time of treatment planning
Must have a lumpectomy performed, with documented negative surgical margins by . cm or more. If re-excision results in negative surgical margins . cm or more, patient is eligible.
In cases of SLL, subjects must have at least one bidimensionally measurable lesion; one of the measurements must be >= . cm in one dimension
Women who have a < . cm or are clinically negative node (cN) after NAC are not eligible
Patients must have minimum head circumference of  cm
Patients will have no more than  distinct lesions, all being =<  cm in greatest dimension, OR  lesion =<  cm in greatest dimension
Patients with positive resection margin or minimal residual disease (< . cm) are also eligible
Transthyretin amyloid (ATTR) cardiomyopathy (CM)
Target (most painful) tumor-bone interface is less then cm from nerve bundles, bowels or bladder.
Inferior margin of the cancer located within  cm from the anal verge as determined by rigid sigmoidoscopy
 Radiographically measurable disease with a clearly demarcated nodal lesion at least . cm in its largest dimension or a target extranodal lesion at least . cm in its largest dimension. In the dose exploration phase in case disease is not radiographically measurable PET positivity (ie, Deauville ?) instead is acceptable.
Subjects with a total tumor size of ? cm following TURBT are eligible. Subjects with a tumor or tumors totaling > cm at screening must undergo a second debulking TURBT to reduce the tumor(s) to ? cm to be eligible for treatment.
Tumor >. cm.
At least one index lesion to be treated measuring - cm amenable to hypofractionated radiation therapy
Bulky lymphadenopathy (>  cm)
Subjects should have <  cm disease by MRI within the previous  weeks (by central read)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted\r\n* Participants must have measurable disease at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >  cm with conventional techniques or as >  cm with spiral CT scan\r\n* Patient must have  or fewer single or multinodular tumors; for patients with a single lesion, lesion must be  cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than  cm in greatest dimension; for patients with three lesions, no lesion may be greater than  cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >=  cm and =<  cm in greatest dimension is allowed
Definitive clinical or radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases or malignant nodes (that enhance with typical features of HCC) > . cm, in sum of maximal diameters (e.g. presence of one . cm metastatic lymph node or two  cm lung lesions); note that benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > . cm
The tumor must be =<  cm (T) in the largest dimension
Patient may have more than one site of recurrence/metastatic disease but only one lesion will be injected that is >=  cm in size (if in the lung, the lesion must be >=  cm and adjacent to the pleura in the lung)
Radiographic contrast enhancement attributable to residual tumor on post-operative imaging performed within  hours of resection must not exceed  cm in biperpendicular planes (>  cm in one plane but <  cm in other planes will be allowed)
Brain metastasis or resection cavity volume <  cm or  cc or >  cm or  cc
Soft tissue lesions >= . cm in longest axis\r\n* Soft tissue lesions < . cm that have been stable for >  months (must not have enlarged >  mm) are permitted
Patients must have no evidence of metastatic disease; metastatic disease:\r\n* Are lesions which are discontinuous from the primary tumor, are not regional lymph nodes and do not share a body cavity with the primary tumor; if there is any doubt whether lesions are metastatic, a biopsy of those lesions should be taken\r\n* Skeletal lesions in adjacent bones (trans-articular)\r\n* Contralateral pleural effusion and contralateral pleural nodules\r\n* Distant lymph node involvement\r\n* Patients with pulmonary nodules are considered to have metastatic disease if the patient has:\r\n** Solitary nodule > . cm or multiple nodules of > . cm unless biopsied and negative for Ewing's\r\n** Biopsies of solitary nodule =< . cm or multiple nodules =< . cm are not required but if performed and positive indicate metastatic disease
Candidates for liver transplantation (listed or screened) according to one of the following criteria:\r\n* Milan criteria (one lesion <  cm or  or fewer lesions each <  cm)\r\n* University of California San Francisco (UCSF) Downstaging criteria (one lesion less than  cm or - lesions each less than  cm with sum of maximum dimensions less than  cm, or - lesions each less than  cm with sum of maximum dimensions less than  cm)\r\n* UCSF All-Comers criteria (UNOS stage T disease beyond UCSF Downstaging criteria)
Patients with pericardial masses >  cm or thoracic lesions larger than  cm will be excluded
Pretreatment positron emission tomography (PET) computed tomography (CT) scan to rule out metastatic disease \r\n* The primary tumor may not be larger than  cm in maximum dimension; mediastinal and hilar lymphadenopathy can be no larger than  cm at any nodal station; if the primary tumor is central in location, defined as within  cm from the tracheobronchial tree, it must be no larger than  cm
Measurable disease\r\n* Mammographic extent of calcifications must be accurately measurable in at least one dimension with each lesion >=  cm and =<  cm\r\n* DCIS must be visible on MRI based on central review\r\n* Patients with palpable DCIS or adenopathy are not eligible to participate\r\n* Patients with multifocal or bilateral disease are eligible
If there was a total or partial thyroidectomy completed within  months of enrollment, the surgical specimen must show the area of anaplastic thyroid cancer to be at least  cm in greatest dimension
Pathologically confirmed primary adenocarcinoma of the esophagus that involves the mid (up to  cm), distal, or esophagogastric junction; the cancer may involve the stomach up to  cm
Measurable splenomegaly prior to study entry as demonstrated by palpable spleen measuring greater than or equal to (>=)  cm below the left costal margin OR spleen volume of >=  cm^ measured by MRI
TN- or TN-b tumors at =<  cm from the A-V margin (below the peritoneal reflection) or the rectosigmoid junction
Tumors of less than  cm thickness from the rectal mucosa documented at the time of staging images
Single enhancing lesion that is > cm, but <  cm in cross-sectional dimension, including thalamic tumor (?  cm)
Metastatic disease, unresectable disease involving one or more sites including liver, lung, lymph nodes and peritoneum, with each nodule measuring =<  cm OR no more than two sites of disease (two nodules) > . cm
Either FDG-avid on FDG-PET or measurable disease by CT on cross sectional imaging: > . cm for nodal lesion, > . cm for extra nodal lesion.
Palpable splenomegaly or hepatomegaly of more than or equal to  cm below left or right, respectively, costal margin on physical exam
Patients with primary tumors >  cm
Presence of an index lesion between  and  cm
Palpable splenomegaly at least  cm below the left costal margin
Untreated central nervous system metastases that are either symptomatic or greater than  cm at time of therapy; lesions that are > cm that have been irradiated and in the opinion of the PI or sub-I no longer represent active disease may be allowed
Implant near (< cm) the prostate
Must have measurable disease, including one of the following: absolute lymphocyte count greater than /uL, lymphadenopathy greater than . cm in longest dimension, splenomegaly (palpable at least  cm below the costal margin or radiographically enlarged), bone marrow biopsy with residual CLL cells, or resultant bone marrow dysfunction (platelet count <  k/uL, hemoglobin <  g/dL)
Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue develop within the past -months that are =< . cm or <  cm^
MRI (completed within  hours after surgery) documenting gross total resection consisting of no gadolinium enhancement; or subtotal resection consisting of linear enhancement with (or without) nodular gadolinium enhancement measuring no greater than  cm x  cm x  cm total volume or  mm^ in cross sectional area
An uninterrupted cm margin must be technically feasible around biopsy scar or primary melanoma.
Have measurable disease consisting of a minimal volume of  cm^
MRI/CT must demonstrate measurable enhancing tumor of at least  cm^ in cross-sectional area to allow assessment of radiographic response
After completion of all chemotherapy, lung metastases must be =<  cm
Palpable splenomegaly at least  cm below left costal margin
At least one lesion that measures >. cm
No single lesion larger than  cm
Pathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases or peritoneal disease; the maximum dimension of the tumor must be =<  cm
Patients must have measured disease, defined as at least  cm x  cm of contrast enhancing disease
Measurable disease of at least . cm as documented by radiographic technique
EXPANSION PHASE ONLY: Evaluable or measurable disease with the largest nodule measuring less than  cm in greatest dimension by radiographic imaging after debulking procedure
Patients tumor(s) to be treated is (are) =< . cm or =<  cm^
Spinal metastatic lesion being treated must be =< cm in greatest dimension
Patients whose tumors are located less than  cm from the ventricles
Presence of an index lesion between  and  cm
At least one measurable VHL related lesion, which is undergoing surveillance, and patient is not at immediate risk of needing intervention for this or other lesions; biopsy is not required given the known likely etiology and natural history in the setting of a positive genetic test\r\n* Brain: asymptomatic hemangioblastoma, >= . cm\r\n* Spine: asymptomatic hemangioblastoma, >= . cm\r\n* Renal: solid mass suspicious for renal cell carcinoma (RCC) >=  cm or cystic mass (Bosniak -) >=  cm\r\n* Pancreas: solid mass >=  cm and =<  cm suspicious for neuroendocrine tumor, or neuroendocrine tumor >  cm but not considered operable\r\n* Eye: asymptomatic peripapillary and/or macular hemangioblastoma, any size\r\n* Adrenal: asymptomatic or controlled pheochromocytoma greater than  cm in size
Measurable disease on cross sectional imaging of at least  cm
Longest uni-dimensional measurement of contrast enhancing tumor >=  cm; tumors exceeding this limit may be eligible and any question should be directed to a radiation oncology investigator and the MSK PI
Asymptomatic and untreated but > cm in the longest dimension
Splenic enlargement extending >  cm below the left costal margin
The planning target volume (PTV), defined as residual T post-contrast enhancing tumor and/or resection cavity plus . cm margin, must measure =<  cm^ in volume; this volume will not be known at the initial consultation; it will be determined once the final radiation plan is completed
Large tumors >  cm
CT scans showing involvement of ? clearly demarcated lesions measuring ? . cm
Group B: T tu;mor (> cm buty <  cm);
Massive tumor (>  cm in greatest dimension)
Have a planned low circular stapled or transanally hand sewn anastomosis ? cm from the anal verge.
Spleen  cm below the inferior left costal margin as measured by manual palpation.
Measurable, non-bony disease (at least one lesion on radiographic or physical exam assessment measuring >=  cm in longest axis), as demonstrated by imaging or physical exam performed =<  days of study entry, provided no anti-tumor therapies or interventions have occurred in that time period
Patients must be amenable to receiving  dose of HSV intra-operatively with planned HSV injection sites >=  cm from the ventricular system AND meet at least one of the criteria below based upon pre-surgical magnetic resonance imaging (MRI):\r\n* Tumor is >=  cm from the ventricular system\r\n* Patients whose tumors that are =<  cm from the ventricular system are eligible if there is sufficient space within the tumor cavity and/or residual tumor to perform the HSV  injections that are >=  cm from the ventricular system
Patients in whom the targeted volume within the tumor is located deeper than  cm from the skin
Target volume in tumor is less than  cm from neurovascular bundles, major blood vessels, bowel or bladder
Confirmed extra hepatic metastases. Patients with indeterminate hepatic hilar lymph nodes up to . cm in greatest dimension, or with indeterminate lung nodules (single lesion between -. cm, or multiple smaller lesions with a total diameter ?  cm) may be included if metastatic disease is deemed unlikely
Tumor >= . cm from skin as defined by breast ultrasound
Locally advanced head and neck (HN) squamous cell carcinoma (SCC), stages III, IV, and bulky (>  cm^ volume) stage II, excluding larynx and nasopharynx, of no more than  cm^ volume base on CT scan
Must have a documented diagnosis of CLL/ SLL requiring treatment (per IWCLL guidelines). In addition: a. Presence of at least one clinically measurable lesion: i. nodal lesion that measures ? . cm in longest dimension (LD) and ? . cm in longest perpendicular dimension (LPD), or ii. spleen that measures ?  cm in longest vertical dimension (LVD) with a minimum of  cm enlargement, or iii. liver that measures ?  cm in LVD with a minimum of  cm enlargement, or iv. peripheral blood B lymphocyte count > /uL.
Palpable primary breast tumor measuring >= . cm on physical exam or imaging prior to neoadjuvant chemotherapy
Operable tumor >=  cm by standard two dimensional (D) ultrasound (largest unidimensional measurement) and less than  weeks after completion of standard NAC
At least one measurable lesion that is > . cm in at least one dimension
Palpable splenomegaly of more than or equal to  cm below left costal margin on physical exam
Patient's esophageal tumor length exceeds that which can be treated with a single stent (maximum lesion length .cm)
At least  of the approximately  patients treated must have measurable disease, defined as at least one, contrast-enhancing lesion measuring at least  cm in  planes (axial, coronal, or sagittal).
?  cm in any dimension.
Does the patient have either () a single, enhancing tumor recurrence/progression that is ?  cm in greatest dimension, or () multiple enhancing tumor recurrences/progressions within the same surgical field where the sum of their greatest dimensions is ?  cm?
At least one intracranial lesion >=. cm but <=. cm that can be treated with surgical resection in the opinion of the treating physicians, and for which immediate local therapy is not clinically indicated
Measurable disease in the breast or axilla that measures at least  cm by either clinical or radiographic measurement
Radiographically measurable disease (>=  focus of lymphoma measuring >= . cm)
Maximum tumor length of  cm at time of brachytherapy treatment start
Patients must have at least one measurable PN, defined as a lesion of at least  cm measured in one dimension; patients who underwent surgery for resection of a PN are eligible provided the PN was incompletely resected and is measurable
Lateral pelvic separation greater than  cm and/or anterior-posterior separation greater than  cm which are incompatible with MR for Calculating Attenuation (MRCAT) reconstruction
Bidimensionally measurable disease with at least  lesion >= . cm in a single dimension
Tumor size =<  cm in greatest dimension \r\n- For NSCLC lesions, staging studies must identify the lesion as T N M, or T (=<  cm) N M, or T (=<  cm) N M
Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (Lung:  lesions total, <  cm, or  single lesion of up to . cm; Lymph nodules in one single anatomic area (pelvis, abdomen or chest): any number, <  cm).
Subjects with tumors lying <  cm from sensitive structures such as the ureter, prostate or adjacent bowel
Absence of the following:\r\n* Malignant ascites\r\n* Extensive carcinomatosis (in the opinion of the investigator)\r\n* Bulky, diffuse adenopathy (>  lymph nodes >  cm each)\r\n* Extensive metastatic disease to the lungs (>  tumors >  cm each)
Tumors with a depth of not greater than . cm from a laparoscopically accessible surface-meaning no part of the tumor should be deeper than . cm from the surface
Tumors greater than . cm at their widest point
Subjects with tumors lying <  cm from sensitive structures such as the ureter, renal vessels or adjacent bowel
Maximum tumor dimension =<  cm
Must meet criteria for initiation of treatment, consisting of:\r\n* Aggressive histology, or \r\n* Indolent histology with one of the following markers of large tumor burden:\r\n** Any nodal or extranodal tumor mass >=  cm in greatest dimension\r\n** >=  nodal masses that are each >=  cm in greatest dimension\r\n** Systemic symptoms\r\n** Cytopenias (leukocytes <  x ^/L and/or platelets,  x ^/L)\r\n** Substantial splenomegaly\r\n** Serous effusion (pleural effusion or peritoneal ascites)\r\n** Orbital or epidural involvement\r\n** Ureteral compression\r\n** Leukemic phase (malignant cells >=  x ^/L)
Target (treated) tumor is less then cm from nerve bundles, bowels or bladder.
Splenomegaly (presence of a palpable spleen whose border could be felt more than  cm below the costal margin)
Disease criteria:\r\n* Cohort A\r\n** CLL\r\n*** Disease burden: lymph node size <  cm and/or extra-nodal involvement <  cm AND\r\n***  p deletion (detected by any assay) (>= % of cells involved if assay is conventional cytogenetics or fluorescence in situ hybridization [FISH]) or NOTCH mutation at any time point during disease course; patient should have received at least  line of therapy; prior ibrutinib therapy is permitted OR\r\n*** Relapsed/refractory CLL >=  lines of therapy; prior ibrutinib therapy is permitted\r\n** MCL\r\n*** Disease burden: lymph node size <  cm and/or extra-nodal involvement <  cm\r\n*** Relapsed/refractory MCL >=  line of therapy; prior ibrutinib therapy is permitted; prior autologous HCT is permitted\r\n*** MCL blastoid variant in first complete response (CR) or high risk MCL being considered for allo HCT in CR\r\n* Cohort B\r\n** FL\r\n*** Disease burden: lymph node size <  cm and/or extra-nodal involvement <  cm AND\r\n*** Relapsed/refractory FL >=  lines of therapy; prior ibrutinib therapy is permitted\r\n** HD\r\n*** Disease burden: lymph node size <  cm and/or extra-nodal involvement <  cm AND\r\n*** Relapsed/refractory HD >=  lines of therapy
Inter-incisor distance > . cm
Thyromental distance >  cm
Inter-incisor distance < . cm
Thyromental distance <  cm
Measurable metastasis to liver with at least one dimension >= . cm; known extrahepatic disease should be limited to lymph nodes of less than  cm and/or bone metastases
Girth >=  cm circumferential difference and/or volume >=  mL compared to the uninvolved upper extremity at any  cm segment
Skin thickness =<  cm (from skin to pleura)
Needle length =<  cm
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of  or more lesions that measure at least . cm in the longest dimension (as assessed radiographically)
The greatest dimension of the tumor is less than  cm before surgery
Patients with proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by at least  cm)
Patients with palpable splenomegaly >=  cm below coastal margin (only applicable to patients with CML)
Tumors located <  cm of staple lines or other metal objects.
Tattoos, scars, active lesions, or rashes =<  cm of the intended site of study treatment
HCCs must fall within the Milan/United Network for Organ Sharing (UNOS) T criteria ( lesion - cm or  lesions all =<  cm without evidence of vascular invasion/metastasis)
At least  cm circumferential Barretts esophagus segment length (CM by Prague C & M criteria)
Minimum of  cm circumferential Barrett's mucosa on endoscopy or at least  cm maximal contiguous extent of Barrett's mucosa
Typically, pancreatic tumors must be less than . cm in greatest axial dimension at the time of treatment planning but final determination of eligibility will be based upon satisfying the radiation normal tissue constraints
Implant near (< cm) the prostate
Documented splenomegaly of at least  cm below the costal margin as measured on inspiration by physical exam.
Large waist circumference \r\n* >=  cm (>=  inches) or \r\n* >=  cm (>=  inches) for Asian Americans, individuals with polycystic ovary syndrome, or individuals with non-alcoholic fatty liver disease
The tumor must be >=  cm and =<  cm
Bullae > cm located in vicinity of target nodule or tunnel
At least one lesion by CT or MRI ?  cm
Posterior lesions that would be >  cm distance from Calypso detector plate
Measurable disease on MRI defined as tumor measuring at least  cm in two perpendicular dimensions
Center of suspicious lesion is not deeper than . cm
Tumor must measure >=  cm on CT
The patient must have a newly diagnosed primary malignant brain tumors (World Health Organization [WHO] grade III or IV glial-based tumors) and not have had a complete surgical resection and by contrast MRI (obtained for clinical purposes within  days prior to FMISO study) have residual tumor >= . cm in greatest diameter and will be receiving radiotherapy or newly diagnosed brain metastasis (>= . cm in greatest diameter or dimension) and will be receiving radiotherapy; an anatomic imaging study (clinical MRI of the brain) must be current and have been obtained within  days prior to the research PET imaging sessions; in patients with a primary brain tumor the patient may be studied after biopsy or after surgery if an incomplete surgical resection has occurred and >= . cm of enhancing tumor is present; only patients intended to receive radiation therapy will be eligible
Minimum tumor dimension >=  cm (preferably >=  cm)
Patients with tumors <  cm
Patients will be deemed not candidates for surgical resection and therefore ineligible for this study based on imaging criteria alone, if CT chest, abdomen, pelvis demonstrates:\r\n* Any disease in the thoracic cavity >=  cm\r\n* Any suprarenal lymphadenopathy >=  cm\r\n* Liver metastases >=  cm\r\n* Disease in the porta hepatis or gallbladder fossa >=  cm\r\n* Pleural effusion >= % volume of the chest cavity on chest x-ray\r\n* Omental extension to the stomach, spleen, or lesser sac\r\n* Extension to the pelvic sidewall (this criteria may also be assessed on physical examination\r\n* Involvement of the root of the mesentery
Either the primary tumor or at least one of the metastatic lesions must be >=  cm
Melanoma deposit is deemed inaccessible to microscopic observation during the operative procedure (i.e., lesion is less than . cm or is not clearly visible to the naked eye)
At least one brain metastasis must be >=  cm to allow adequate quantitative imaging measurement for DSC-PMR
Tumors beyond Milan criteria; this trial does not enroll patients with tumors beyond Milan criteria even from region(s) where transplant listing might still be permissible due to a special regional arrangement; any of the following will exclude the patient from the trial:\r\n* Evidence of extrahepatic tumor\r\n* Unifocal HCC >  cm in diameter\r\n* Multifocal HCCs,  or more in number\r\n* Multiple ( or more) HCCs with at least one tumor >=  cm
A biopsy-proven histological diagnosis of locally advanced, recurrent or metastatic melanoma of any stage that is surgically resectable and be scheduled for clinically indicated surgical removal of one or more melanoma tumors; additionally, patients must have a resectable tumor nodule >=  cm^ (i.e., either a spherical tumor at least . cm in diameter or a tumor measuring at least  x  x  cm)
Have a primary tumor measuring >= . cm
Have a surgical target =<  cm from the skin when lying supine
At least one suspected soft tissue sarcoma tumor that is considered by the investigator to be: () accessible for percutaneous injection and () at least . cm in shortest dimension for patients undergoing an incisional biopsy, or at least  cm in shortest dimension for patients undergoing an excisional biopsy/tumor resection. Tumors should not be selected if the Investigator believes them to be necrotic or exhibit signs of radiation-induced fibrosis.
The presence of at least one lesion, measuring ?  cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or hepatitis B or C infection.
Diagnosed with primary or metastatic tumor <  cm located in peripheral lung
Pathologic lymphadenopathy (at least five discrete nodes each > cm in their longest dimension)
Splenomegaly (>  cm in the longest dimension)
Hepatomegaly (> cm in the longest dimension)
At least  distinct measurable metastatic sites, which are  cm or larger